Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring.

OBJECTIVE To assess differences in activity and immobility during sleep between patients with Parkinson's disease (PD) and healthy subjects and to evaluate the relations of clinical variables with the motor activity measures in patients with PD. DESIGN Survey, case series. SETTING University hospital outpatient neurology department and urban population in Leiden, the Netherlands. Motor activity was recorded during 6 successive nights at home with a wrist-worn activity monitor. PARTICIPANTS Eighty-nine patients with PD and 83 age-matched healthy controls. MAIN OUTCOME MEASURES For each subject, three mean measures reflecting activity or immobility during the nocturnal period were calculated. RESULTS Compared with the healthy elderly subjects, patients with PD have an elevated nocturnal activity level and an increased proportion of time with movement, indicating a more disturbed sleep. The mean duration of nocturnal immobility periods was similar for both groups. This measure, however, did reflect the self-reported disturbed sleep maintenance in both groups. The daily dose of levodopa or the use of dopamine agonists in patients not receiving levodopa, rather than disease severity, proved to be the best predictors of nocturnal activity. CONCLUSIONS We hypothesize that in mildly to moderately affected patients with PD, levodopa or dopamine agonists cause sleep disruption by their effects on sleep regulation. In more severely affected patients, the beneficial effects of these drugs on nocturnal disabilities that cause sleep disruption in PD prevail.

[1]  D. J. Mullaney,et al.  An activity-based sleep monitor system for ambulatory use. , 1982, Sleep.

[2]  A. Laihinen,et al.  Sleep movements and associated autonomic nervous activities in patients with Parkinson's disease , 1987, Acta neurologica Scandinavica.

[3]  M. H. Rediehs,et al.  Sleep in old age: focus on gender differences. , 1990, Sleep.

[4]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[5]  R. Dobbs,et al.  Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa. , 1987, British journal of clinical pharmacology.

[6]  W. Weiner,et al.  Sleep Disruption in the Course of Chronic Levodopa Therapy: An Early Feature of the Levodopa Psychosis , 1982, Clinical neuropharmacology.

[7]  T. Pillar,et al.  Sleep‐wake cycles in multi‐infarct dementia and dementia of the Alzheimer type , 1991, Neurology.

[8]  J. Parkinson.  An Essay on the Shaking Palsy , 2002 .

[9]  A. Borbély.  New techniques for the analysis of the human sleep-wake cycle , 1986, Brain and Development.

[10]  J. Vardi,et al.  EEG sleep study in parkinsonian patients under bromocryptine treatment. , 1978, European Neurology.

[11]  N. A. Blackburn,et al.  The nighttime problems of Parkinson's disease. , 1988, Clinical neuropharmacology.

[12]  C. Cianchetti,et al.  Clinical pharmacology as an approach to the study of biochemical sleep mechanisms: the action of L-dopa. , 1974, Confinia Neurologica.

[13]  J. Montplaisir,et al.  The effects of L-dopa on periodic leg movements and sleep organization in narcolepsy. , 1989, Clinical neuropharmacology.

[14]  S. Fahn.  Unified Parkinson's Disease Rating Scale , 1987 .

[15]  J. Montplaisir,et al.  The effects of L‐dopa on excessive daytime sleepiness in narcolepsy , 1991, Neurology.

[16]  R. Roos,et al.  A new approach in the assessment of motor activity in Parkinson's disease. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[17]  D F Kripke,et al.  Wrist-actigraphic estimation of sleep time. , 1980, Sleep.

[18]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[19]  R P Lesser,et al.  Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy , 1979, Neurology.

[20]  M. Mintz,et al.  Unilateral dopamine deficit and lateral eeg asymmetry: sleep abnormalities in hemi-Parkinson's patients. , 1982, Electroencephalography and clinical neurophysiology.

[21]  M. Tinetti.  Performance‐Oriented Assessment of Mobility Problems in Elderly Patients , 1986, Journal of the American Geriatrics Society.

[22]  J. Askenasy,et al.  Parkinsonian tremor loses its alternating aspect during non-REM sleep and is inhibited by REM sleep. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[23]  K. Pettigrew,et al.  Motor activity and sleep duration as a function of age in healthy men , 1987, Physiology & Behavior.

[24]  W C Dement,et al.  “White Paper” on Sleep and Aging , 1982, Journal of the American Geriatrics Society.

[25]  G. Di Chiara,et al.  Sleep induced by low doses of apomorphine in rats. , 1979, Electroencephalography and clinical neurophysiology.

[26]  H. Schulz,et al.  Rate and Distribution of Body Movements during Sleep in Humans , 1983, Perceptual and motor skills.

[27]  B. Kemp,et al.  Ambulatory Monitoring of Sleep‐Wakefulness Patterns in Healthy Elderly Males and Females (>88 Years): The “Senieur” Protocol , 1992 .

[28]  J. Meerwaldt,et al.  Madopar HBS in Parkinson patients with nocturnal akinesia , 1988, Clinical Neurology and Neurosurgery.

[29]  J. G. Dijk,et al.  Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[30]  D. Rodenstein,et al.  Ambulatory evaluation of sleep disturbance and therapeutic effects in sleep apnea syndrome by wrist activity monitoring. , 1987, The American review of respiratory disease.

[31]  A. Nicholson,et al.  Dopaminergic transmission and the sleep-wakefulness continuum in man , 1990, Neuropharmacology.

[32]  H. Kamphuisen,et al.  Actigraphically recorded motor activity and immobility across sleep cycles and stages in healthy male subjects , 1993, Journal of sleep research.

[33]  A. Lees.  A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease. , 1987, European neurology.

[34]  C. Markham,et al.  Sleep in patients with Parkinson's disease and normal subiects prior to and following levodopa administration , 1971, Clinical pharmacology and therapeutics.

[35]  F. Mcdowell,et al.  Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. , 1975, Annals of internal medicine.

[36]  J. Askenasy,et al.  Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy , 1985, Neurology.

[37]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[38]  R. Wyatt,et al.  Effect of L-Dopa on the Sleep of Man , 1970, Nature.

[39]  W. Weiner,et al.  Sleep disorders and sleep effect in Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.